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and Ming-Hai Wang1,2*Erratum
Unfortunately, the original version of this article [1] con-
tained an error. The name of one of the authors, Sharad
Sharma, was not included in the author list.
The correct author list and the new “Authors’ contri-
butions” section have been correctly included in full in
this erratum and updated in the original article.
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